Patents by Inventor Marc E. Lippman
Marc E. Lippman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110123441Abstract: The generation and validation of a novel monoclonal GREB1 antibody (GREB1ab). Methods for the prognosis, diagnosis, assessment of disease progression, severity and outcome utilize GREB1 molecules as biomarkers. The GREB1 antibody is also a useful tool for investigations focused on the expression, distribution and function of GREB1 in normal and cancer tissues.Type: ApplicationFiled: October 20, 2010Publication date: May 26, 2011Applicants: UNIVERSITY OF MIAMI, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Marc E. Lippman, Harry James Hnatyszyn, Mingli Liu, James M. Rae
-
Patent number: 7268240Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: GrantFiled: May 28, 2004Date of Patent: September 11, 2007Inventors: Leo J. Romanczyk, Jr., Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Patent number: 6849746Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: GrantFiled: January 31, 2003Date of Patent: February 1, 2005Assignee: Mars, Inc.Inventors: Leo J. Romanczyk, Jr., Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Publication number: 20040236123Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: ApplicationFiled: May 28, 2004Publication date: November 25, 2004Applicant: M&M/Mars Inc.Inventors: Leo J. Romanczyk, Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Publication number: 20040235941Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: ApplicationFiled: June 14, 2004Publication date: November 25, 2004Applicant: Mars, IncorporatedInventors: Leo J. Romanczyk, Marc E. Lippman
-
Publication number: 20030176620Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: ApplicationFiled: January 31, 2003Publication date: September 18, 2003Applicant: Mars IncorporatedInventors: Leo J. Romanczyk, Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Patent number: 6566104Abstract: Enzymatic RNA molecules which cleave ErbB-4 mRNA and uses thereof.Type: GrantFiled: June 23, 2000Date of Patent: May 20, 2003Assignee: Georgetown UniversityInventors: Careen K. Tang, Marc E. Lippman
-
Patent number: 6528664Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: GrantFiled: December 14, 2001Date of Patent: March 4, 2003Assignee: Mars, IncorporatedInventors: Leo J. Romanczyk, Jr., Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Publication number: 20020128493Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: ApplicationFiled: December 14, 2001Publication date: September 12, 2002Applicant: Mars, IncorporatedInventors: Leo J. Romanczyk, Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Publication number: 20020111325Abstract: The present invention relates to a vascular endothelial cell inhibitor, VEGI, capable of inhibiting angiogenesis in cellular models and tumourigenesis in animal models, and methods of use.Type: ApplicationFiled: December 12, 2001Publication date: August 15, 2002Applicant: Human Genome Sciences, Inc.Inventors: Lu-Yuan Li, Yifan Zhai, Guo-Liang Yu, Jian Ni, Marc E. Lippman, Craig A. Rosen
-
Patent number: 6420572Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.Type: GrantFiled: October 9, 1998Date of Patent: July 16, 2002Assignee: Mars, IncorporatedInventors: Leo J. Romanczyk, Jr., Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
-
Patent number: 6143740Abstract: The invention provides a method of inhibiting cancer cell growth, and thereby of treating cancer comprising administering to a mammal afflicted with cancer an effective amount of the compound of formula (I), wherein the variables of R.sub.1, and R.sub.2 have the meanings defined in the specification. The present invention also provides novel compounds of formula (I) as well as novel pharmaceutical compositions and intermediates useful for preparing compounds of formula (I). The figure illustrates the structure and binding activity of compounds of the invention and some of the rifamycin analogs.______________________________________ ##STR1##______________________________________ Compounds R.sub.1 = ______________________________________ A1 --OH A2 --OH A3 --OH A4 --OH A5 --OH A6 --OH A7 --OH - A8 ##STR2## ______________________________________ Compounds R.sub.Type: GrantFiled: August 16, 1999Date of Patent: November 7, 2000Assignee: Georgetown UniversityInventors: Dajun Yang, Shaomeng Wang, Alan P. Kozikowski, Marc E. Lippman
-
Patent number: 6040290Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. The present invention also pertains to a method for inhibiting the growth of adenocarcinoma cells.Type: GrantFiled: August 26, 1996Date of Patent: March 21, 2000Assignee: Georgetown UniversityInventors: Marc E. Lippman, Ruth Lupu
-
Patent number: 5874528Abstract: The present invention relates to blocking peptides which are capable of binding to ligands for the erbB-2 receptor or the epidermal growth factor receptor (EGFR). The blocking peptides of the invention are used to detect the presence of such ligand molecules. In addition, the blocking peptides are useful in inhibiting or preventing the growth of adenocarcinoma cells which express the erbB-2 receptor or the EGFR.Type: GrantFiled: October 27, 1994Date of Patent: February 23, 1999Assignee: Georgetown UniversityInventors: Ruth Lupu, Marc E. Lippman
-
Patent number: 5869618Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.Type: GrantFiled: October 31, 1995Date of Patent: February 9, 1999Inventors: Marc E. Lippman, Ruth Lupu
-
Patent number: 5578482Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.A method for inhibiting the growth of adenocarcinoma cells in a human, which cells overexpress the oncogene erbB-2, which entails administering to said human an amount of a 30 kDa glycoprotein effective to inhibit the growth of said cells.Type: GrantFiled: July 26, 1993Date of Patent: November 26, 1996Assignee: Georgetown UniversityInventors: Marc E. Lippman, Ruth Lupu